Advances and Prospects in the Treatment of Pancreatic Cancer
Huaiyu Duan,Li Li,Shiming He
DOI: https://doi.org/10.2147/IJN.S413496
IF: 7.033
2023-07-20
International Journal of Nanomedicine
Abstract:Huaiyu Duan, 1, &ast Li Li, 2, &ast Shiming He 1 1 School of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, People's Republic of China; 2 Department of Hepatobiliary Pancreatic Oncology, Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shiming He, Email Pancreatic cancer is a highly malignant and incurable disease, characterized by its aggressive nature and high fatality rate. The most common type is pancreatic ductal adenocarcinoma (PDAC), which has poor prognosis and high mortality rate. Current treatments for pancreatic cancer mainly encompass surgery, chemotherapy, radiotherapy, targeted therapy, and combination regimens. However, despite efforts to improve prognosis, and the 5-year survival rate for pancreatic cancer remains very low. Therefore, it's urgent to explore novel therapeutic approaches. With the rapid development of therapeutic strategies in recent years, new ideas have been provided for treating pancreatic cancer. This review expositions the advancements in nano drug delivery system, molecular targeted drugs, and photo-thermal treatment combined with nanotechnology for pancreatic cancer. It comprehensively analyzes the prospects of combined drug delivery strategies for treating pancreatic cancer, aiming at a deeper understanding of the existing drugs and therapeutic approaches, promoting the development of new therapeutic drugs, and attempting to enhance the therapeutic effect for patients with this disease. Keywords: pancreatic cancer, nano drug delivery system, molecular targeted drugs, photo-thermal treatment Pancreatic cancer is a type of digestive system tumor, the incidence of which has been increasing in recent years with a 5-year survival rate close to 10%. 1–3 Generally, obesity and diabetes were known as risk factors for this disease, and newly developed or worsened diabetes may be indicative of PDAC. In addition, genetic changes also played a significant role in the development of PDAC. 4,5 At present, surgery remains the primary treatment for pancreatic cancer. For pancreatic cancer patients who were not eligible for surgical resection, chemotherapy, radiotherapy, and immunotherapy may be considered as treatment options. However, their efficacy was not very satisfactory because of drug resistance. 6–8 Therefore, it's pressing to develop novel and more targeted therapies. With the advancement of modern science and technology, nanoparticles possessed several advantageous characteristics including a large specific surface area, adjustable pore size, high drug loading capacity, excellent biocompatibility, and targeted delivery to tumor tissues with high efficiency. 9,10 The co-delivery of gemcitabine and cisplatin via nanoparticles could exert a synergistic effect on PDAC. 11 The matrix of PDAC comprises the extracellular matrix, vascular system, and tumor-associated fibroblasts, which can form into a dense tumor mesenchyme that impedes the drug delivery. 12 Nano-drug delivery systems have the potential to overcome the tumor interstitial barrier to achieve targeted drug delivery. 13 The most frequently overexpressed genes in pancreatic cancer, such as KRAS, CDKN2A, TP53, and SMAD4, which have been identified as potential targets for molecular targeted therapy. 14 In recent years, molecular targeted therapy for pancreatic cancer has been rapidly developed, including epidermal growth factor receptor inhibitors, and anti-EGFR antibodies, which can block the activation of downstream tyrosine kinase phosphorylation and subsequently inhibit the proliferation of tumor cells. However, these drugs may generate resistance. 15,16 Pancreatic stellate cells were closely associated with drug-resistance of chemotherapy, which could promote the growth, invasion, and metastasis of tumors. 17 The precise release of payloads could be achieved through coupling antibodies with nanoparticles. 18 The combination of nanotechnology and molecular targeting holds great promise for curing pancreatic cancer in the future. Photothermal conversion agents or photosensitizers were used in photothermal therapy to absorb energy and generate heat under near-infrared light irradiation of a certain wavelength, thus efficiently eradicating tumor cells. The combination of phototherapy and chemotherapy and phototherapy and gene therapy based on non-viral nanocarriers may be a potential treatment for PDAC. 19,20 In spite of the dense tumor interstitium in pancreatic tumor tissue that may obstruct the light irradiation and drug delivery, the application of nano-drug de -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology